{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:10:40Z","timestamp":1771488640787,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["1IK2HX003007"],"award-info":[{"award-number":["1IK2HX003007"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","award":["CIN 13-404"],"award-info":[{"award-number":["CIN 13-404"]}],"id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11606-024-08898-1","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T17:01:36Z","timestamp":1719939696000},"page":"2142-2149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-4390","authenticated-orcid":false,"given":"Jessica J.","family":"Wyse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summer","family":"Newell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Morasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah S.","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis I.","family":"Lovejoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"8898_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","volume":"3","author":"KM Keyes","year":"2022","unstructured":"Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052. https:\/\/doi.org\/10.1016\/j.dadr.2022.100052","journal-title":"Drug Alcohol Depend Rep."},{"key":"8898_CR2","unstructured":"CDC. U.S. overdose deaths in 2021 increased half as much as in 2020 - but are still up 15%. Published 2022. Accessed April 26, 2023. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm"},{"key":"8898_CR3","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550. https:\/\/doi.org\/10.1136\/bmj.j1550","journal-title":"BMJ."},{"key":"8898_CR4","unstructured":"National Academies of Sciences E and Medicine. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019."},{"issue":"2","key":"8898_CR5","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622-e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622","journal-title":"JAMA Netw Open."},{"issue":"3","key":"8898_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. https:\/\/doi.org\/10.7326\/M17-3107","journal-title":"Ann Intern Med."},{"issue":"8","key":"8898_CR7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s11606-023-08027-4","volume":"38","author":"JJ Wyse","year":"2023","unstructured":"Wyse JJ, Shull S, Lindner S, et al. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities. J Gen Intern Med. 2023;38(8):1871-1876. https:\/\/doi.org\/10.1007\/s11606-023-08027-4","journal-title":"J Gen Intern Med."},{"key":"8898_CR8","doi-asserted-by":"publisher","unstructured":"Lindner SR, Hart K, Manibusan B, McCarty D, McConnell KJ. State- and County-Level Geographic Variation in Opioid Use Disorder, Medication Treatment, and Opioid-Related Overdose Among Medicaid Enrollees. JAMA Health Forum. 2023;4(6):e231574. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.1574","DOI":"10.1001\/jamahealthforum.2023.1574"},{"issue":"1","key":"8898_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/10826084.2022.2149244","volume":"58","author":"JW Bresett","year":"2023","unstructured":"Bresett JW, Kruse-Diehr AJ. Medications for Opioid Use Disorder in Rural United States: A Critical Review of the Literature, 2004\u20132021. Subst Use Misuse. 2023;58(1):111-118. https:\/\/doi.org\/10.1080\/10826084.2022.2149244","journal-title":"Subst Use Misuse."},{"issue":"2","key":"8898_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/ADM.0000000000000719","volume":"15","author":"AK Finlay","year":"2021","unstructured":"Finlay AK, Harris AH, Timko C, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. J Addict Med. 2021;15(2):143. https:\/\/doi.org\/10.1097\/ADM.0000000000000719","journal-title":"J Addict Med."},{"issue":"13","key":"8898_CR11","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.12562","volume":"322","author":"PJ Joudrey","year":"2019","unstructured":"Joudrey PJ, Edelman EJ, Wang EA. Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States. JAMA. 2019;322(13):1310-1312. https:\/\/doi.org\/10.1001\/jama.2019.12562","journal-title":"JAMA."},{"issue":"3","key":"8898_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/08897077.2018.1509251","volume":"39","author":"H Valenstein-Mah","year":"2018","unstructured":"Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Subst Abuse. 2018;39(3):286-288. https:\/\/doi.org\/10.1080\/08897077.2018.1509251","journal-title":"Subst Abuse."},{"key":"8898_CR13","unstructured":"Clinical Pharmacist Practicioner (CPP) Role in Substance Use Disorders (SUD). Published online June 2023. https:\/\/www.pbm.va.gov\/PBM\/CPPO\/Documents\/ExternalFactSheet_CPPRoleinSubstanceUseDisorders_508.pdf"},{"key":"8898_CR14","unstructured":"Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abuse. Published online 2020:1-8."},{"key":"8898_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106603","volume":"152","author":"DT Moore","year":"2021","unstructured":"Moore DT, Wischik DL, Lazar CM, Vassallo GG, Rosen MI. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub. Prev Med. 2021;152:106603. https:\/\/doi.org\/10.1016\/j.ypmed.2021.106603","journal-title":"Prev Med."},{"issue":"3","key":"8898_CR16","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11606-020-06255-6","volume":"35","author":"ET Chang","year":"2020","unstructured":"Chang ET, Oberman RS, Cohen AN, et al. Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care. J Gen Intern Med. 2020;35(3):918-926. https:\/\/doi.org\/10.1007\/s11606-020-06255-6","journal-title":"J Gen Intern Med."},{"issue":"3","key":"8898_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275-282. https:\/\/doi.org\/10.1080\/08897077.2020.1787299","journal-title":"Subst Abuse."},{"issue":"14","key":"8898_CR18","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1007\/s11606-021-07274-7","volume":"37","author":"HJ Hagedorn","year":"2022","unstructured":"Hagedorn HJ, Gustavson AM, Ackland PE, et al. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. J Gen Intern Med. 2022;37(14):3594-3602. https:\/\/doi.org\/10.1007\/s11606-021-07274-7","journal-title":"J Gen Intern Med."},{"issue":"4","key":"8898_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/acem.14683","volume":"30","author":"C Sasson","year":"2023","unstructured":"Sasson C, Dieujuste N, Klocko R, et al. Barriers and facilitators to implementing medications for opioid use disorder and naloxone distribution in Veterans Affairs emergency departments. Acad Emerg Med. 2023;30(4):289-298. https:\/\/doi.org\/10.1111\/acem.14683","journal-title":"Acad Emerg Med."},{"issue":"2","key":"8898_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","volume":"39","author":"JJ Wyse","year":"2018","unstructured":"Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abuse. 2018;39(2):139-144. https:\/\/doi.org\/10.1080\/08897077.2018.1452327","journal-title":"Subst Abuse."},{"issue":"1","key":"8898_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12913-018-3108-8","volume":"18","author":"ME Ohl","year":"2018","unstructured":"Ohl ME, Carrell M, Thurman A, et al. \u201cAvailability of healthcare providers for rural veterans eligible for purchased care under the veterans choice act.\u201d BMC Health Serv Res. 2018;18(1):315. https:\/\/doi.org\/10.1186\/s12913-018-3108-8","journal-title":"BMC Health Serv Res."},{"key":"8898_CR22","unstructured":"US Department of Veterans Affairs, Veterans Health Administration, Office of the Assistant Deputy Under Secretary for Health for Policy and Planning. Rurality Definitions Methods and Work Group Report: March, 2013."},{"issue":"5","key":"8898_CR23","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s11606-020-06339-3","volume":"36","author":"BA Howell","year":"2021","unstructured":"Howell BA, Abel EA, Park D, et. al. Validity of incident opioid use disorder (OUD) diagnoses in administrative data: a chart verification study. J Gen Intern Med. 2021;36(5):1264-1270. https:\/\/doi.org\/10.1007\/s11606-020-06339-3","journal-title":"J Gen Intern Med."},{"issue":"3","key":"8898_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/0038038509103208","volume":"43","author":"C May","year":"2009","unstructured":"May C, Finch T. Implementing, embedding, and integrating practices: an outline of normalization process theory. Sociology. 2009;43(3):535-554.","journal-title":"Sociology."},{"key":"8898_CR25","doi-asserted-by":"publisher","unstructured":"Kislov R, Pope C, Martin GP, Wilson PM. Harnessing the power of theorising in implementation science. Implement Sci. 2019;14(1):103. Published 2019 Dec 11. https:\/\/doi.org\/10.1186\/s13012-019-0957-4","DOI":"10.1186\/s13012-019-0957-4"},{"key":"8898_CR26","doi-asserted-by":"crossref","unstructured":"Booth A, Hannes K, Harden A, Noyes J, Harris J, Tong A. COREQ (consolidated criteria for reporting qualitative studies). Guidel Report Health Res Users Man. Published online 2014:214-226.","DOI":"10.1002\/9781118715598.ch21"},{"issue":"3","key":"8898_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11606-020-06258-3","volume":"35","author":"F Sandbrink","year":"2020","unstructured":"Sandbrink F, Oliva EM, McMullen TL, et al. Opioid Prescribing and Opioid Risk Mitigation Strategies in the Veterans Health Administration. J Gen Intern Med. 2020;35(3):927-934. https:\/\/doi.org\/10.1007\/s11606-020-06258-3","journal-title":"J Gen Intern Med."},{"issue":"2","key":"8898_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.anclin.2023.02.004","volume":"41","author":"RE Courtney","year":"2023","unstructured":"Courtney RE, Schadegg MJ. Chronic, Noncancer Pain Care in the Veterans Administration: Current Trends and Future Directions. Anesthesiol Clin. 2023;41(2):519-529. https:\/\/doi.org\/10.1016\/j.anclin.2023.02.004","journal-title":"Anesthesiol Clin."},{"issue":"1","key":"8898_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13722-021-00263-5","volume":"16","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Danner AN, Malte CA, et al. Clinical Leaders and Providers\u2019 Perspectives on Delivering Medications for the Treatment of Opioid Use Disorder in Veteran Affairs\u2019 facilities. Addict Sci Clin Pract. 2021;16(1):55. https:\/\/doi.org\/10.1186\/s13722-021-00263-5","journal-title":"Addict Sci Clin Pract."},{"issue":"2","key":"8898_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1037\/a0022776","volume":"25","author":"AJ Gordon","year":"2011","unstructured":"Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215-224. https:\/\/doi.org\/10.1037\/a0022776","journal-title":"Psychol Addict Behav."},{"issue":"5","key":"8898_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/ADM.000000000000078","volume":"15","author":"AT Kelley","year":"2021","unstructured":"Kelley AT, Dungan MT, Gordon AJ. Barriers and facilitators to buprenorphine prescribing for opioid use disorder in the Veterans Health Administration During COVID-19. J Addict Med. 2021;15(5):439-440. https:\/\/doi.org\/10.1097\/ADM.000000000000078","journal-title":"J Addict Med."},{"issue":"12","key":"8898_CR32","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s11606-023-08116-4","volume":"38","author":"PE Ackland","year":"2023","unstructured":"Ackland PE, Kenny ME, Clothier BA, et al. What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities. J Gen Intern Med. 2023;38(12):2647-2654. https:\/\/doi.org\/10.1007\/s11606-023-08116-4","journal-title":"J Gen Intern Med."},{"issue":"9","key":"8898_CR33","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s11606-022-07975-7","volume":"38","author":"AT Kelley","year":"2023","unstructured":"Kelley AT, Wilcox J, Baylis JD, et al. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives. J Gen Intern Med. 2023;38(9):2147-2155. https:\/\/doi.org\/10.1007\/s11606-022-07975-7","journal-title":"J Gen Intern Med."},{"issue":"3","key":"8898_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jsat.2013.09.002","volume":"46","author":"CA Green","year":"2014","unstructured":"Green CA, McCarty D, Mertens J, et al. A qualitative study of the adoption of buprenorphine for opioid addiction treatment. J Subst Abuse Treat. 2014;46(3):390-401. https:\/\/doi.org\/10.1016\/j.jsat.2013.09.002","journal-title":"J Subst Abuse Treat."},{"issue":"10","key":"8898_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.12788\/fp.0186","volume":"38","author":"JF Spelman","year":"2021","unstructured":"Spelman JF, Edens EL, Maya S, et al. A facility-wide plan to increase access to medication for opioid use disorder in primary care and general mental health settings. Fed Pract. 2021;38(10):460-464. https:\/\/doi.org\/10.12788\/fp.0186","journal-title":"Fed Pract."},{"key":"8898_CR36","doi-asserted-by":"publisher","unstructured":"Wyse JJ, Mackey K, Kansagara D, et al. Expanding access to medications for opioid use disorder through locally-initiated implementation. Addict Sci Clin Pract. 2022;17(1):32. Published 2022 Jun 20. https:\/\/doi.org\/10.1186\/s13722-022-00312-7","DOI":"10.1186\/s13722-022-00312-7"},{"issue":"2","key":"8898_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ajad.13260","volume":"31","author":"AJ Gordon","year":"2022","unstructured":"Gordon AJ, Kenny M, Dungan M, et al. Are x\u2010waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x\u2010waiver trainings. Am J Addict. 2022;31(2):152-158. https:\/\/doi.org\/10.1111\/ajad.13260","journal-title":"Am J Addict."},{"key":"8898_CR38","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s11606-019-05582-7","volume":"35","author":"ST Rinne","year":"2020","unstructured":"Rinne ST, Mohr DC, Swamy L, Blok AC, Wong ES, Charns MP. National burnout trends among physicians working in the Department of Veterans Affairs. J Gen Intern Med. 2020;35:1382-1388. https:\/\/doi.org\/10.1007\/s11606-019-05582-7","journal-title":"J Gen Intern Med."},{"issue":"1","key":"8898_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11606-022-07707-x","volume":"38","author":"J Porter","year":"2023","unstructured":"Porter J, Boyd C, Skandari MR, Laiteerapong N. Revisiting the Time Needed to Provide Adult Primary Care. J Gen Intern Med. 2023;38(1):147-155. https:\/\/doi.org\/10.1007\/s11606-022-07707-x","journal-title":"J Gen Intern Med."},{"key":"8898_CR40","doi-asserted-by":"publisher","first-page":"758849","DOI":"10.3389\/fpsyt.2021.758849","volume":"12","author":"S Ghahramani","year":"2021","unstructured":"Ghahramani S, Lankarani KB, Yousefi M, et. al. A Systematic Review and Meta-analysis of Burnout Among Healthcare Workers During COVID-19. Front Psychiatry. 2021;12:758849. https:\/\/doi.org\/10.3389\/fpsyt.2021.758849","journal-title":"Front Psychiatry."},{"issue":"1","key":"8898_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1370\/afm.2775","volume":"20","author":"EL Kelly","year":"2022","unstructured":"Kelly EL, Cunningham A, Sifri R, Pando O, Smith K, Arenson C. Burnout and Commitment to Primary Care: Lessons from the Early Impacts of COVID-19 on the Workplace Stress of Primary Care Practice Teams. Ann Fam Med. 2022;20(1):57-62. https:\/\/doi.org\/10.1370\/afm.2775","journal-title":"Ann Fam Med."},{"key":"8898_CR42","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s11606-018-4679-0","volume":"33","author":"ST Edwards","year":"2018","unstructured":"Edwards ST, Marino M, Balasubramanian BA, et al. Burnout Among Physicians, Advanced Practice Clinicians and Staff in Smaller Primary Care Practices. J Gen Intern Med. 2018;33:2138-2146. https:\/\/doi.org\/10.1007\/s11606-018-4679-0","journal-title":"J Gen Intern Med."},{"issue":"4","key":"8898_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/ajhp\/zxaa405","volume":"78","author":"BM DeRonne","year":"2021","unstructured":"DeRonne BM, Wong KR, Schultz E, Jones E, Krebs EE. Implementation of a Pharmacist Care Manager Model to Expand Availability of Medications for Opioid use Disorder. Am J Health Syst Pharm. 2021;78(4):354-359. https:\/\/doi.org\/10.1093\/ajhp\/zxaa405","journal-title":"Am J Health Syst Pharm."},{"issue":"5","key":"8898_CR44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ADM.0000000000000059","volume":"8","author":"JD Lee","year":"2014","unstructured":"Lee JD, Vocci F, Fiellin DA. Unobserved \u201chome\u201d Induction Onto Buprenorphine. J Addict Med. 2014;8(5):299-308. https:\/\/doi.org\/10.1097\/ADM.0000000000000059","journal-title":"J Addict Med."},{"key":"8898_CR45","unstructured":"Substance Abuse Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients and Families. Updated 2020. Published online 2020. https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP20-02-01-006_508.pdf"},{"key":"8898_CR46","doi-asserted-by":"publisher","first-page":"108272","DOI":"10.1016\/j.jsat.2020.108272","volume":"124","author":"L Wang","year":"2021","unstructured":"Wang L, Weiss J, Ryan EB, Waldman J, Rubin S, Griffin JL. Telemedicine Increases Access to Buprenorphine Initiation During the COVID-19 Pandemic. J Subst Abuse Treat. 2021;124:108272. https:\/\/doi.org\/10.1016\/j.jsat.2020.108272","journal-title":"J Subst Abuse Treat."},{"key":"8898_CR47","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.dadr.2023.100164","volume":"7","author":"A Silwal","year":"2023","unstructured":"Silwal A, Talbert J, Bohler RM, et al. State Alignment with Federal Regulations in 2022 to Relax Buprenorphine 30-patient Waiver Requirements. Drug Alcohol Depend Rep. 2023;7:100164. https:\/\/doi.org\/10.1016\/j.dadr.2023.100164","journal-title":"Drug Alcohol Depend Rep."},{"issue":"2","key":"8898_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, Catlin M, Andrilla CHA, et. al. Barriers to Primary Care Physicians Prescribing Buprenorphine. Ann Fam Med. 2014;12(2):128-133. https:\/\/doi.org\/10.1370\/afm.1595","journal-title":"Ann Fam Med."},{"issue":"3","key":"8898_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic Review of Rural-specific Barriers to Medication Treatment for Opioid use Disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273-288. https:\/\/doi.org\/10.1080\/00952990.2019.1694536","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"1","key":"8898_CR50","first-page":"93","volume":"15","author":"JR DeFlavio","year":"2015","unstructured":"DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15(1):93-103.","journal-title":"Rural Remote Health."},{"issue":"13","key":"8898_CR51","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1177\/1049732316654870","volume":"26","author":"L Birt","year":"2016","unstructured":"Birt L, Scott S, Cavers D, Campbell C, Walter F. Member Checking: A Tool to Enhance Trustworthiness or Merely a Nod to Validation? Qual Health Res. 2016;26(13):1802-1811. https:\/\/doi.org\/10.1177\/1049732316654870","journal-title":"Qual Health Res."},{"issue":"4","key":"8898_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/YCO.0000000000000943","volume":"37","author":"A Cheetham","year":"2024","unstructured":"Cheetham A, Grist E, Nielsen S. Pharmacist-prescriber Collaborative Models of Care for Opioid use Disorder: An Overview of Recent Research. Curr Opin Psychiatry. 2024;37(4):251-257. https:\/\/doi.org\/10.1097\/YCO.0000000000000943 .","journal-title":"Curr Opin Psychiatry."},{"issue":"3","key":"8898_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","volume":"41","author":"G Cochran","year":"2020","unstructured":"Cochran G, Bruneau J, Cox N, Gordon AJ. Medication Treatment for Opioid use Disorder and Community Pharmacy: Expanding Care During a National Epidemic and Global Pandemic. Subst Abuse. 2020;41(3):269-274. https:\/\/doi.org\/10.1080\/08897077.2020.1787300","journal-title":"Subst Abuse."},{"key":"8898_CR54","doi-asserted-by":"publisher","unstructured":"McLeman B, Gauthier P, Lester LS, et al. Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations. Addict Sci Clin Pract. 2024;19(1):18. Published 2024 Mar 18. https:\/\/doi.org\/10.1186\/s13722-024-00452-y","DOI":"10.1186\/s13722-024-00452-y"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08898-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-08898-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-08898-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:07:50Z","timestamp":1764266870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-08898-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["8898"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-08898-1","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"This research was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the VA Portland Health Care System.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate:"}},{"value":"No author reports having any potential conflict of interest with this study. The content is solely the responsibility of the authors and does not represent the official views of the Department of Veterans Affairs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}